Research programme: age-related macular degeneration therapeutics - Gemini Therapeutics

Drug Profile

Research programme: age-related macular degeneration therapeutics - Gemini Therapeutics

Alternative Names: GEM-103; GR-1005; GR-1006; GR-1007; GR-1008; GR-1009; GR-1017; GR-1024

Latest Information Update: 28 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gemini Therapeutics
  • Class Eye disorder therapies; Gene therapies; Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration

Most Recent Events

  • 17 Oct 2017 Preclinical trials in Age-related macular degeneration in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top